Novo nordisk to lower u.s. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in january 2024

Novo nordisk has been working to identify a sustainable approach to reduce insulin costs for patients that addresses changes in health policy and market shifts lower list prices build on long-standing history of affordability initiatives already in place which can be accessed at novocare.com novo nordisk currently provides co-pay support for a number of insulin products meaning eligible patients can pay $25-35 for their insulin plainsboro, n.j. , march 14, 2023 /prnewswire/ -- novo nordisk inc. today announced it is lowering the u.s. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes.
NVO Ratings Summary
NVO Quant Ranking